The use of healthcare systems data for RCTs

Toader, Alice-Maria ORCID: 0000-0002-3801-3486, Gamble, Carrol L ORCID: 0000-0002-3021-1955, Dodd, Susanna ORCID: 0000-0003-2851-3337 and Williamson, Paula R ORCID: 0000-0001-9802-6636 (2024) The use of healthcare systems data for RCTs. Trials, 25 (1). 95-.

PDF s13063-023-07846-4.pdf - Open Access published version Download (990kB) | Preview

Abstract

<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Healthcare systems data (HSD) has the potential to optimise the efficiency of randomised controlled trials (RCTs), by decreasing trial-specific data demands. Therefore, the use of HSD in trials is expected to increase. In 2019, it was estimated that 47% of NIHR-funded trials were planning to use HSD. We aim to understand the extent and nature of its current use and its evolution over time.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>We identified a cohort of RCTs within the NIHR Journals Library that commenced after 2019 and were described as being in progress on 6 June 2022. Details on the source and use of HSD were extracted from eligible RCTs. The use of HSD was categorised according to whether it was used as the sole data source for outcomes and whether the outcomes were primary or secondary. HSD is often insufficient for patient-reported outcomes (PROs). We aimed to determine methods used by trialists for collecting PRO data alongside HSD.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Of the 84 eligible studies, 52 (62%) planned to use HSD and 79 (94%) planned to collect PROs. The number of RCTs planning to use HSD for at least one outcome was 28 (54%) with 24 of these planning to use HSD as the sole data source for at least one outcome.</jats:p> <jats:p>The number of studies planning to use HSD for primary and secondary outcomes was 10 (20%) and 21 (40%) respectively. The sources of HSD were National Health Service (NHS) Digital (<jats:italic>n</jats:italic> = 37, 79%), patient registries (<jats:italic>n</jats:italic> = 7, 29%), primary care (<jats:italic>n</jats:italic> = 5, 21%), The Office for National Statistics (ONS) (<jats:italic>n</jats:italic> = 3, 13%) and other (<jats:italic>n</jats:italic> = 2, 8%).</jats:p> <jats:p>PROs were collected for 92% of the trials planning to use HSD. Methods for collection of PROs included in-person (<jats:italic>n</jats:italic> = 26, 54%), online (<jats:italic>n</jats:italic> = 22, 46%), postal (<jats:italic>n</jats:italic> = 18, 38%), phone (<jats:italic>n</jats:italic> = 14, 29%) and app (<jats:italic>n</jats:italic> = 2, 4%).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>HSD is being used in around two thirds of the studies but cannot yet be used to support PRO data collection within the cohort we examined. Comparison with an earlier cohort demonstrates an increase in the number of RCTs planning to use HSD.</jats:p> </jats:sec>

Item Type:	Article
Uncontrolled Keywords:	Humans, Data Collection, Telephone, Delivery of Health Care, Randomized Controlled Trials as Topic
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Population Health
Depositing User:	Symplectic Admin
Date Deposited:	02 Feb 2024 10:35
Last Modified:	02 Feb 2024 10:45
DOI:	10.1186/s13063-023-07846-4
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3178327